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Abstract Abnormally low levels of the cyclin-dependent kinase
inhibitor p27Kip1 are found frequently in human carcinomas, and
these levels correlate directly with both histological aggressive-
ness and patient mortality. p27Kip1 is haplo-insufficient for tumor
suppression. Thus, p27Kip1 may be a useful molecule for the
development of cancer therapies. To know the possible mechan-
isms underlying transcriptional control, we previously cloned the
promoter region of human p27Kip1 gene. We report here the
characterization of the 5P-regulatory region of the human p27Kip1
gene. Promoter analysis using 5P-deletion mutants revealed that
a 39-bp region between 3549 and 3511 was required for
maximal promoter activity. Point mutation analysis revealed
that a CCAAT box within this region was essential for promoter
activity. Gel shift assays and cotransfection experiments using a
dominant negative form of the NF-Y transcription factor showed
that NF-Y directly regulates p27Kip1 transcription through this
CCAAT box. This finding might provide a clue to approach the
mechanism of tumorigenesis.
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1. Introduction
p27Kip1 is an inhibitor of multiple cyclin-dependent kinases,
and is thought to be an essential participant in the strict
regulation of the cell cycle both in vitro and in vivo. Although
mutations in p27Kip1 are found rarely in human tumors [1],
abnormally low levels of the p27Kip1 protein are found fre-
quently in human tumors, and reduced expression of the pro-
tein correlates well with poor survival among patients with
breast [2,3], lung [4], prostate [5], and gastric carcinomas [6].
Furthermore p27Kip1 was recently shown to be haplo-insu⁄-
cient for tumor suppression [7]. That is, inactivation of only
one allele, or moderate decrease in protein expression, is suf-
¢cient to predispose to tumorigenesis. A potentially important
strategy for cancer therapeutics will be to restore expression of
tumor suppressor proteins. For this purpose, p27Kip1 may be a
useful molecule. Recent work has shown an increase in
p27Kip1 mRNA levels after incubation of neuroblastoma cells
with thyroid hormone, embryonal carcinoma cells with reti-
noic acid, or gastric carcinoma cells with interferon-L [8^10].
In these experimental systems, the increase in p27Kip1 tran-
scripts augments the p27Kip1 protein level as well as stabiliza-
tion of the p27Kip1 protein, suggesting that transcriptional
regulation of p27Kip1 is more generally important. Neverthe-
less, little is known about the regulatory mechanisms of
p27Kip1 transcription. For this purpose, we previously cloned
the human p27Kip1 gene promoter and reported that nucleo-
tide position 3774 to 3435 relative to the translation start site
is essential to its promoter activity [11].
To improve our knowledge of the transcriptional regulation
of the human p27Kip1 gene, the next step would involve the
characterization of the elements found in the promoter region.
We describe here the cis-elements and trans-acting factors that
regulate p27Kip1 gene expression at the basal level.
2. Materials and methods
2.1. Cell culture
The human cervical carcinoma cell line C33A, the human osteosar-
coma cell line U2OS cells and the human osteosarcoma cell line
MG63 cells were maintained in Dulbecco’s modi¢ed Eagle’s medium
with 10% fetal bovine serum and incubated at 37‡C in a humidi¢ed
atmosphere of 5% CO2.
2.2. Plasmid construction and mutagenesis
The human p27Kip1-luciferase fusion plasmid, p27PF, and some
deletion mutants, p27ApaI, p27A£II, and p27SacII, were previously
generated [11]. Other deletion mutants, p27No. 1, p27No. 2, and
p27No. 12 were generated using a Mungbeans-Exonuclease III sys-
tem, the Kilo-sequence Deletion Kit (Takara, Tokyo, Japan).
Plasmids with point mutations in p27PF, p27mSp1-1, p27mSp1-2,
and p27mCTF, were generated by site-directed mutagenesis [12] using
the Quick Change Site-Directed Mutagenesis Kit (Stratagene). The
top strands of the oligonucleotides were as follows, with mutations
indicated by underlines: p27mSp1-1, 5P-CAGCCTCGGCGGGATG-
GCTCCCGCCG-3P ; p27mSp1-2, 5P-CGGGGCGGCTCCTACCGC-
CGCAACCAATG-3P ; p27mCTF, 5P-GCCGCCGCAACCTTTGGA-
TCTCCTCC-3P. To avoid undesirable mutations, each ApaI-HindIII
fragment corresponding to 3774/312 of these three mutants was
subcloned back into ApaI and HindIII digested p27PF. The integrity
of all generated constructs were con¢rmed by restriction analysis and
sequencing.
2.3. Transient transfection and luciferase assay
C33A cells (3U105 cells) and MG63 cells (3U105 cells) were seeded
into 6-cm diameter tissue culture dishes. After 24 h, 2 Wg of reporter
plasmid and 1 Wg of pACTL-gal, a plasmid containing the L-galacto-
sidase driven by actin promoter, were cotransfected into cells using
the calcium phosphate co-precipitation method [13]. Cells were har-
vested after 48 h or 24 h and preparation of extracts and luciferase
assays were performed as described previously [14]. The luciferase
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activity of each cell lysate was measured and was normalized by L-
galactosidase or protein activities in the cell lysates. All the transfec-
tion assays were carried out in triplicate. Each experiment was re-
peated at least twice. A dominant negative NF-YA expression plasmid
(pNF-YA29) is a kind gift from Dr. R. Mantovani at the University
of Milano.
2.4. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared according to the method of An-
drews and Faller [15]. The reaction mixture for the gel shift assay
(20 Wl ¢nal volume) contained 20 mM Tris-HCl (pH 8.0), 50 mM
NaCl, 1 mM DTT, 1 mM EDTA, 10% glycerol, 0.05% Nonidet
P-40, 5 Wg of bovine serum albumin (BSA), 2 Wg of poly(dI-dC),
and 5 Wg of nuclear extract. After preincubation for 5 min at room
temperature, probe DNA (approximately 2 ng, 20 000 cpm) was
added to the mixture, and the binding reaction was allowed to pro-
ceed at room temperature for 20 min. The product was then resolved
by electrophoresis on 5% acrylamide-bisacrylamide (29:1), 0.5UTBE
non-denaturing gel at 10 V/cm for 120 min. The sequences of the top
strands of oligonucleotides used in these studies are as follows, with
mutations indicated by underlines: WT3530/3510, 5P-CTAGCGC-
CGCAACCAATGGATCTCC-3P ; MUT3530/3510, 5P-CTAGCGC-
CGCAACCTTTGGATCTCC-3P ; NF-I, 5P-CTAGTTTTGGATTG-
AAGCCAATATGATAA-3P [16]; NF-Y, 5P-ACTTTTAACCAATC-
AGAAAAATCTAG-3P [17] ; CP2, 5P-CTAGTGACCAGTTCCAG-
CCACTCTTTA-3P [18]. Competition analyses were performed by
mixing an indicated amount of the appropriate competitor DNA to
the binding reaction prior to addition of nuclear extracts. In supershift
experiments, antibody (IgG fraction) against NF-YB or antibody
against C/EBP-K (sc-7204X; Santa Cruz) was added to the incubation
mixture containing nuclear protein before addition of probe DNA.
Antibody against NF-YB was kindly provided by Dr. R. Mantovani.
3. Results and discussion
We have reported previously that a 339-bp region between
3774 and 3435 relative to the translation start site is essential
for human p27Kip1 promoter activity [11]. To further de¢ne
cis-elements that are required for the human p27Kip1 promoter
activity, several additional deletion mutants between 3774
and 3435 were generated and transiently transfected into
C33A, MG63, and U2OS cells. We used C33A and U2OS
cells to represent cells whose p53 and RB genes are mutated
or intact, respectively, and MG63 cells to represent cells that
carry rearrangements in the p53 gene but contain an intact
RB gene. As shown in Fig. 1, deletions up to position 3549
(p27No. 2) did not result in signi¢cant changes in the pro-
moter activity, whereas the promoter activity was decreased
markedly using a deletion up to 3511 (p27No. 12) in C33A
cells. A similar result was obtained in U2OS and MG63 cells
(data not shown). These results showed that potential regula-
tory elements appeared to be located downstream from 3549,
and a drastic decrease in promoter activity using a deletion up
to 3511 suggested that the region between 3549 and 3511
(3112 and 374 relative to the transcription start site) con-
tained the elements required for basal promoter activity.
The sequence of this 39-bp region carried two consensus
Sp1 binding sites and one CCAAT box (CTF site). In this
study, we termed the two Sp1 sites in the upstream region
Sp1-1 and Sp1-2 (Fig. 2). To determine whether the two
Sp1 sites and the CCAAT box were involved in the regulation
of p27Kip1 transcription, a series of mutations of the full-size
promoter construct, p27PF, having mutations in each Sp1 site
or the CCAAT box were generated, and were termed
p27mSp1-1, p27mSp1-2, and p27mCTF, respectively (Fig.
2). These constructs were transiently transfected into C33A,
MG63, and U2OS cells, and their luciferase activities were
analyzed. As shown in Fig. 2, a 2-bp mutation in the CCAAT
box signi¢cantly reduced the promoter activity of p27PF in all
cell lines. Furthermore, a mutation in the Sp1-1 site but not
the Sp1-2 also signi¢cantly reduced the promoter activity of
p27PF in U2OS cells (Fig. 2, lower panel), whereas the reduc-
tion of promoter activity caused by a mutation in the Sp1-1
site was smaller in C33A and MG63 cells than in U2OS cells
(Fig. 2, MG63 data not shown). This result indicated that the
CCAAT box was indispensable for the maximum basal pro-
moter activity of the p27Kip1 gene and the requirement for the
Sp1-1 site for promoter activity depended on the cell line.
To identify trans-acting factor(s) that interacts with the
Fig. 1. E¡ects of 5P-deletion mutations on the promoter activity of the human p27Kip1 gene in C33A cells. The 5P-deletion mutants of the pro-
moter region of the p27Kip1 gene were fused to the luciferase gene. Two Wg of each plasmid was transiently transfected into C33A cells with
1 Wg of pACTL-gal, and luciferase activities were analyzed after 48 h. The luciferase activity in the cell extracts was determined as described in
Section 2. Each construct is shown schematically on the left. Data are shown as means (bars, standard error) (n = 3).
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CCAAT box, we performed EMSA using 32P-labeled oligo-
nucleotides spanning 3530 to 3510 of the human p27Kip1
promoter (WT3530/3510) that contained the CCAAT box.
Three shifted bands were observed when the probe was incu-
bated with the C33A cell nuclear extract. Only the slowest
migrating complex was speci¢cally competed out by excess
unlabeled WT3530/3510 but not MUT3530/3510 in which
the CCAAT had been mutated to CCTTT (data not shown),
suggesting that nuclear protein(s) can bind speci¢cally to the
CCAAT sequence in the WT3530/3510 probe.
It has been shown that CCAAT sequences can interact with
various nuclear proteins including NF-Y(CP1), NF1(CTF),
CP2, and C/EBP [17^21]. To elucidate which nuclear proteins
bind to the 3524/3519 CCAAT box, we performed compet-
itive EMSAs using oligonucleotides carrying CCAAT sequen-
ces that had been reported to bind to each of these transcrip-
tion factors in a speci¢c manner [16^18,22]. As shown in Fig.
3, binding of the factor to the WT3530/3510 probe was
e¡ectively competed by a molar excess of oligonucleotides
containing an NF-Y binding site (NF-Y, lanes 7 and 8) as
well as by the WT3530/3510 probe (lanes 3 and 4). On the
other hand, oligonucleotides containing NF1 or CP2 binding
sites did not e⁄ciently compete with the binding (Fig. 3, lanes
5, 6, 9, and 10). In addition, when the gel shift band was
generated using the NF-Y probe, it was competed with excess
amounts of the WT3530/3510 and the NF-Y probes, but not
the MUT3530/3510 probe (data not shown). These results
suggested that the ubiquitous transcription factor NF-Y can
bind to the CCAAT box of the p27Kip1 promoter.
To con¢rm that the factor binding to the WT3530/3510
probe was NF-Y, we performed supershift experiments using
antibodies. NF-Y is composed of three subunits, NF-YA,
NF-YB, and NF-YC and we used antibodies raised against
the B subunit of NF-Y [23^25], or against C/EBP-K[26] as a
Fig. 2. Mutation analysis to identify the cis-elements required for the basal promoter activity of p27Kip1 gene in C33A and U2OS cells. Three
di¡erent mutants, shown on the left, were identical to the wild-type p27PF except for the mutation in capital letters. Two Wg of each con-
structed plasmid was transiently transfected into C33A or U2OS cells with 1 Wg of pACTL-gal, and luciferase activities were analyzed after
48 h. Data are shown as means (bars, standard error) (n = 3). *P6 0.05.
Fig. 3. Binding of nuclear proteins from C33A cells to the CCAAT
box of the p27Kip1 gene and competition analysis. Electrophoretic
mobility shift assay was carried out with nuclear extracts prepared
from C33A cells. A set of oligonucleotides containing the CCAAT
box between 3530 and 3510 (WT3530/3510) was used as a probe.
Nuclear extracts were incubated with 32P-labeled WT3530/3510 in
the absence (3) (lanes 1 and 2) or in the presence of 100- or 1000-
fold amounts of various unlabeled oligonucleotides that can bind to
each CCAAT binding protein. The speci¢c retarded band containing
CCAAT box binding protein(s) is indicated on the left.
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negative control. As shown in Fig. 4, in the presence of anti-
NF-YB antibody but not anti-C/EBP-K antibody, the com-
plex was supershifted (lanes 2^5). This demonstrated that
NF-Y binds to the CCAAT box of the p27Kip1 promoter.
To further con¢rm the involvement of NF-Y in the regu-
lation of p27Kip1 transcription, we cotransfected p27PF or
p27mCTF with a dominant negative NF-YA mutant expres-
sion plasmid (pNF-YA29) [25,27,28] or the parental expres-
sion vector (pSG5). As shown in Fig. 5, the luciferase activity
from p27PF was reduced to about 70% when cotransfected
with pNF-YA29. This result suggested that NF-Y at least
partially regulates p27Kip1 transcription via the CCAAT box
within its promoter.
The results presented here suggest that the transcription
factor, NF-Y, plays a central role in regulating the basal level
of the p27Kip1 promoter activity by direct binding to the
CCAAT box. Currently, there is no precise report about the
relationship between NF-Y expression and the level of p27Kip1
in tumor cells. Future investigation of mutations in the
CCAAT box of the p27Kip1 gene promoter and the expression
of NF-Y in various malignancies, whose level of p27Kip1 is
low, should reveal the precise role of p27Kip1 and NF-Y in
malignant tumors. From the standpoint of cancer therapeu-
tics, p27Kip1 may be a possible target for the development of
strategies for cancer therapeutics, by means of restoring ex-
pression of tumor suppressor proteins [7]. On the other hand,
NF-Y is a ubiquitously expressed multi-component factor that
interacts with the CCAAT box, a common element present in
various mammalian gene promoters. NF-Y appears to coop-
erate functionally with di¡erent transcription factors or tissue
speci¢c factors [29^31], but the mechanism is not yet under-
stood. Investigation of this mechanism might provide useful
information for the development of agents that promote tran-
scription of the p27Kip1 gene in a therapeutic or chemopreven-
tive context, which we have termed gene-regulating chemo-
therapy or chemoprevention [32].
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